Mean percentage improvement from baseline to week 24 in measures of disease activity
| Sulfasalazine(n = 50) | Etanercept (n = 103)* | Etanercept and sulfasalazine (n = 100)† | |
|---|---|---|---|
| CRP, C reactive protein; DAS, Disease Activity Score; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire, EuroQOL, EuroQuality of life; VAS, Visual Analogue Scale. | |||
| *p<0.01 sulfasalazine versus etanercept. | |||
| †p<0.01 combination versus sulfasalazine. | |||
| ‡Median percentage improvement. | |||
| Painful joints | 22.7 | 65.4 | 62.0 |
| Swollen joints | 38.5 | 68.7 | 70.1 |
| Pain VAS | 13.3 | 55.6 | 53.9 |
| HAQ | 9.2 | 35.3 | 40.2 |
| DAS | 19.6 | 48.2 | 49.7 |
| EuroQOL VAS | 20.1 | 64.6 | 67.6 |
| Morning stiffness | −21.1 | 62.8 | 68.5 |
| Physician global assessment | 16.0 | 59.9 | 62.0 |
| Patient global assessment | 13.6 | 50.5 | 53.5 |
| ESR | 0.2 | 37.6 | 43.0 |
| CRP‡ | 32.9 | 69.9 | 66.7 |